FIGURE 1.
Trial profile. aOne patient randomized to BELA+EVL received TAC+MMF for the 2-y study period. BELA, belatacept; EVL, everolimus; ITT, intention-to-treat; MMF, mycophenolate mofetil; TAC, tacrolimus.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.